Trial Profile

Auxora for the Treatment of AKI and Modulation of Injurious "Crosstalk" With the Lung: A Randomized Control Trial (KOURAGE)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zegocractin (Primary)
Indications Acute kidney injury
Focus Therapeutic Use
Acronyms KOURAGE

Most Recent Events

29 Jul 2026 According to a CalciMedica media release, CalciMedica is evaluating the future development of Auxora in AKI, with no current plans to resume dosing in the KOURAGE trial.
24 Jun 2026 According to a CalciMedica media release, the U.S. Food and Drug Administration (FDA) has reviewed a protocol amendment and interim safety data Following the applicable review period, the Company has received no comments from the FDA on the submission and the trial may continue to dose patients.
06 May 2026 Planned End Date changed from 1 Apr 2026 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com